Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback